Chugai Reports Vabysmo Sustains Vision Gains at 48 Weeks in Angioid Streaks Trial
I'm PortAI, I can summarize articles.
Chugai Pharmaceutical Co. Ltd. announced positive 48-week results from the Phase III NIHONBASHI trial of Vabysmo® in Japanese patients with angioid streaks. The trial showed sustained vision gains and reduced retinal edema, with Vabysmo being well tolerated. Vabysmo is the first approved drug in Japan for choroidal neovascularization associated with angioid streaks. The results were presented at the Japanese Retina and Vitreous Society's 64th Annual Meeting.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments